Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE 9 Study
2024-513704-34-00Phase 3Completed
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Jun 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN) and Cervical Cancer (CC) comparing Gardasil 9 with Placebo (2 arms). Primary endpoint: Reduction of disease recurrence. Started Jun 2024; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2024-513704-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513704-34-00.